Atezolizumab (Tecentriq) is now the first immunotherapy approved by the Food and Drug Administration for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010.
In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) greatly improved progression-free survival compared with trastuzumab emtansine (Kadcyla), new study results show.
Clinical trial results show people who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage 2 melanomas were less likely to have the cancer come back than those who received no treatment after surgery.
In a large clinical trial, people with HR-positive, HER2-negative metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their first treatment lived about 1 year longer than women treated with letrozole only.
Clinical Trials Information for Patients and Caregivers
This page explains how clinical trials undergo extensive scientific review before people are enrolled and while the study is conducted. It introduces the various groups that review trials and monitor their progress.
Sometimes clinical trials are stopped early, before the planned treatment period has been completed. This page explains several reasons why a trial might end early.
This phase 2 trial will determine whether treatment with the drug docetaxel (Taxotere) leads to fewer or less severe cases of peripheral neuropathy than treatment with paclitaxel (Abraxane) in Black people with early-stage breast cancer. Doctors will also assess the relationship between certain genetic signatures and the likelihood of peripheral neuropathy caused by paclitaxel.
This phase 1 trial will test pomalidomide (Pomalyst) combined with the immunotherapy drug nivolumab (Opdivo) in people with cancers caused by viruses. Doctors will assess the safety and determine the best dose of the combination.
This phase 2 trial will test how well the drug simvastatin (Zocor) works in preventing liver cancer in people with cirrhosis of the liver. Simvastatin is commonly used to treat high cholesterol and triglycerides. Doctors will assign people with advanced liver cirrhosis by chance to receive either simvastatin or placebo for 6 months to see if the drug protects them from developing liver cancer.
